New hope for hepatitis b: 48-Week drug trial launches
NCT ID NCT07519330
First seen Apr 17, 2026 · Last updated Jun 17, 2026 · Updated 14 times
Summary
This study tests a new drug called HH-006 in 45 adults with chronic hepatitis B. Participants will receive the drug for 48 weeks and be monitored for changes in virus levels and liver function. The goal is to see if the drug can safely control the infection and reduce the amount of virus in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing University Three Gorges Hospital
RECRUITINGChongqing, Chongqing Municipality, 400000, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.